We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Blood Gas Analysis and Buffering In Cardiac Arrest (BABICA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01362556
Recruitment Status : Completed
First Posted : May 30, 2011
Last Update Posted : June 3, 2014
Sponsor:
Information provided by (Responsible Party):
Prause Gerhard, MD, Medical University of Graz

Brief Summary:
The debate over the administration of sodium bicarbonate in cardiac arrest has been going on for several decades, swinging like a pendulum from "first-line drug" to "not indicated" to the recent guidelines advocating "a small bolus under special conditions (metabolic acidosis, intoxication, long-term resuscitation)". A targeted, blood-gas controlled application under optimised ventilation conditions has not yet been evaluated prehospitally. Our preliminary studies have shown that an arterial puncture/line as well as measurement of blood gases is feasible in preclinical conditions. This multicentre trial including 5 centres and 10 physician-staffed emergency systems is designed to compare, in a prospective randomised controlled study, the effect of a calculated dosage of sodium bicarbonate based on the patient´s base deficit and weight, on ROSC (= return of spontaneous circulation) and on the secondary survival of cardiac arrest patients. The null hypothesis is that there is no or negative impact on survival.

Condition or disease Intervention/treatment
Cardiac Arrest Drug: Sodium bicarbonate Drug: Sodium Chloride

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 700 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Blood Gas Analysis and Buffering In Cardiac Arrest - A Multicenter, Prospective, Randomised, Double Blind Prehospital Trial to Evaluate the Impact of Early Blood-gas-analysis Targeted Buffer Therapy on ROSC After OOHCA
Study Start Date : March 2011
Primary Completion Date : December 2013
Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cardiac Arrest
U.S. FDA Resources

Arm Intervention/treatment
Placebo Comparator: Sodium Chloride
Group receiving sodium chloride 0.9% after arterial blood gas analysis in cardiac arrest.
Drug: Sodium Chloride

Administration of a calculated amount of sodium chloride 0.9% [SC] after arterial blood gas measurement according to Base Excess [BE] and Body weight [kg].

Formula: SC [ml] = -BE * kg * 0.1

Active Comparator: Sodium Bicarbonate
Group receiving targeted sodium bicarbonate 8% therapy after arterial blood gas analysis in cardiac arrest.
Drug: Sodium bicarbonate

Administration of a calculated amount of sodium bicarbonate 8% [SB] after arterial blood gas measurement according to Base Excess [BE] and Body weight [kg].

Formula: SB [ml] = -BE * kg * 0.1




Primary Outcome Measures :
  1. Rate of return of spontaneous circulation (ROSC) [ Time Frame: Within five hours from start of resuscitation. ]

Secondary Outcome Measures :
  1. Survival to discharge after cardiac arrest [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 5 weeks ]
    Discharge from hospital

  2. Survival after one year of hospital discharge [ Time Frame: One year after event ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • prehospitally started cardiopulmonary resuscitation (CPR)
  • advanced cardiac life support provided
  • age >18 years
  • arterial pH < 7,2
  • arterial BE < -12
  • arterial pCO2 15-75 mmHg
  • arterial pO2 >35 mmHg

Exclusion Criteria:

  • women of childbearing age
  • traumatic cardiac arrest

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01362556


Locations
Austria
Landeskrankenhaus Klagenfurt
Klagenfurt, Carinthia, Austria, 9020
Landesklinikum Wiener Neustadt
Wiener Neustadt, Lower Austria, Austria, 2700
Landeskrankenhaus Bruck / Mur
Bruck / Mur, Styria, Austria, 8600
LKH Graz West
Graz, Styria, Austria, 8020
Medical University Graz
Graz, Styria, Austria, 8036
AKH Linz
Linz, Upper Austria, Austria, 4021
Sponsors and Collaborators
Medical University of Graz
Investigators
Principal Investigator: Gerhard Prause, Prof. Dr. Medical University of Graz

Responsible Party: Prause Gerhard, MD, Prof Dr, Medical University of Graz
ClinicalTrials.gov Identifier: NCT01362556     History of Changes
Other Study ID Numbers: BABICA
First Posted: May 30, 2011    Key Record Dates
Last Update Posted: June 3, 2014
Last Verified: June 2014

Additional relevant MeSH terms:
Heart Arrest
Heart Diseases
Cardiovascular Diseases